Table of contents

  • Brand Names
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Pregnancy and Lactation Implications
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Genes that may be involved
  • Drug Interactions
  • Nutrition/Nutraceutical Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics
  • Special Considerations

Brand Names


Austria: Orencia; Belgium: Orencia; Czech Republic: Orencia; Denmark: Orencia; Estonia: Orencia; Finland: Orencia; France: Orencia; Germany: Orencia; Greece: Orencia; Hungary: Orencia; Ireland: Orencia; Italy: Orencia; Latvia: Orencia; Luxembourg: Orencia; Netherlands: Orencia; Poland: Orencia; Portugal: Orencia; Romania: Orencia; Slovakia: Orencia; Spain: Orencia; Sweden: Orencia; UK: Orencia.

North America

Canada: Orencia; USA: Orencia.

Latin America

Argentina: Orencia.

Drug combinations


Abatacept: (C~1965~H~3080~N~479~O~695~S~16~). Mw: approx. 92000.01 (46000.01 per chain). 1-25-Oncostatin M (human precursor) fusion protein with CTLA-4 (antigen)(human) fusion protein with immunoglobulin G~1~ (human heavy chain fragment). CAS-332348-12-6 (2004).

Pharmacologic Category

Antirheumatic Drugs. (ATC-Code: L04AA24).

Mechanism of action

Blocks CD28 interaction between antigen-presenting cells and T cells. Decreases T-cell proliferation and inhibits production of TNF, interferon-gamma, and interleukin-2. Suppresses inflammation, decreases anti-collagen antibody production, and reduces antigen-specific production of interferon gamma.

Therapeutic use

Treatment of adult rheumatoid arthritis (as monotherapy or in combination with other disease-modifying anti-rheumatic drugs) or juvenile idiopathic arthritis (as monotherapy or in combination with methotrexate).

Pregnancy and lactiation implications

Should be used during pregnancy only if clearly needed (risk of autoimmune disease in fetus). Not recommended during lactation.

Unlabeled use


Hypersensitivity to abatacept or any component of the formulation.

Warnings and precautions

Hypersensitivity, anaphylaxis or anaphylactoid reactions might occur. May affect defenses against malignancies. Risk of lymphoma. Caution with chronic obstructive pulmonary disease (COPD). Screening for viral hepatitis prior to use. Live vaccines should not be given concurrently or within 3 months of discontinuation of therapy.



Legal Notice
Privacy Policy
Cookie Policy


Phone: +34-981-780505
Email: genomicmedicine@wagem.org
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart